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Introduction: Sentinel Lymph Node Biopsy (SLNB) is the standard of care for staging axillary lymph nodes
in women with breast cancer and clinically negative nodes. It is associated with reduced arm morbidity,
moderated or severe lymphoedema, and a better quality of life in comparison with standard axillary
treatment. Unfortunately, skip metastases makes all minimally invasive approaches, such as axillary
sampling, unreliable. The aim of the present clinical prospective study is to evaluate the position of SLN
in an important number of cases and establish the real incidence of skip metastases in clinically node-
negative patients.
Patients and methods: A cohort of 898 female patients with breast carcinoma was considered, from 2001
to 2008. Once SLN was localized, by means of radio-colloid or blue dye staining, and isolated, a biopsy
was performed. Only those positive for metastases were submitted to axillary dissection.
Results: Only in nine cases a SLN was not isolated. We had 819 cases of ﬁrst level SLN (group A) and 69
cases of second level SLN (group B). Considering all of 889 cases, SLN was localized in the second level in
69 patients (7.8%); but if we consider metastatic SLN alone (340 cases), it was in the second level in 23
subjects (6.8%). In total, we had a positive second level SLN in 2.3% of cases (23/889).
Conclusion: Second level SLN could be considered only an anomalous lymphatic axillary drainage and it
does not linked to particular histological variants of the primitive tumour. In our study, skip metastases
were recognized in only 2.6% of cases, therefore, whenever a SLN is not isolated for any reason, the ﬁrst
level sampling represent a viable operative choice.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction of life in comparison with standard axillary treatment [4]. AnSentinel Lymph Node Biopsy (SLNB) is the standard of care for
staging axillary lymph nodes in women with breast cancer and
clinically negative nodes. In particular, if the SLN is not metastatic,
the patient will not undergo a complete axillary lymph-node
dissection (ALND). Results from several trials and meta-analysis,
indicate that total survival, disease-free survival and regional dis-
ease control are statistically equivalent between patients treated
with complete axillary dissection and those who are not treated,
after a negative SLNB [1e3]. SLNB is associated with reduced arm
morbidity, moderated or severe lymphoedema, and a better qualitycological and Stomatological
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rrazzo).
by Elsevier Ltd. All rights reservedalternative technique to SLNB could be represented by axillary
sampling, especially for those cases of difﬁcult lymph node isola-
tion or when SLNB cannot be performed. Unfortunately, this
approach has not been accepted yet, because of skip metastases [5]
which can localize in a second level lymph node, making staging
unreliable. The present clinical prospective study was performed to
evaluate the position of SLN in an important number of cases and
establish the real incidence of skip metastases in clinically node-
negative patients.2. Patients and methods
From January 2001 to December 2008, 898 patients with breast
carcinoma underwent conservative surgery and SLNB; only.
Table 1
Lymph node histologic features after SLNB.
Group A Group B p
Hyperplastic 454 (55.43%) 41 (59.4%) N.S
Micrometastases 97 (10.5%) 6 (8.69%) N.S
Macrometastases 220 (26.9%) 17 (24.6%) N.S
Isolated tumoral cells 48 (5.9%) 5 (7.2%) N.S
Table 3
Number of positive LNs after ALND in SLN positive patients.
Group A Group B p
Single metastatic SLN 175 (56.4%) 14 (60.8%) N.S
Metastatic LNs <3 56 (18.1%) 3 (13.1%) N.S
Metastatic LNs >3 79 (25.5%) 6 (26.1%) N.S
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dissection. Of these 898 patients, 645 had SLN localization by both
radio-colloid and blue dye, and 242 by radio-colloid only. A detailed
report of both methods used to identify the SLN is provided by a
previous trial conducted by the authors [6]. SLN was localized on
the base of Berg classiﬁcation [7]: lateral (level I), posterior (level II),
or medial (level III) to the pectoralis minor muscle. While isolating
the lymph node, operative time was recorded. A complete axillary
dissectionwas performedwhen sentinel nodes resulted positive for
metastases.
A non-parametric statistical analysis was used and categorical
variables were evaluated using the chi-squares test or Fisher's exact
test, where appropriate. A value of p > 0.05 was considered
signiﬁcant.3. Results
Only in nine cases a SLN was not isolated, whereas, for the
remaining 889 patients, we had 819 cases of ﬁrst level SLN (group
A) and 69 cases of second level SLN (group B). Themedian age at the
time of entering the study was 54 (range 30e80) for group B and 55
(range 30e82) for group A. The operative time to perform quad-
rantectomy and SLN biopsy was respectively 44.7 min range:
25e60 min) for group A and 44.8 min (25e60 min) for group B.
Considering all of 889 cases, SLNwas localized in the second level in
69 patients (7.8%); but if we consider metastatic SLN alone (340
cases), it was in the second level in 23 subjects (6.8%). In total, we
had a positive second level SLN in 2.6% of cases (23/889). No sta-
tistically signiﬁcant correlation was found between histopatho-
logical variables of patients with SLN localized at ﬁrst level and
those with second level SLN (see Table 1). Three-hundred and ten
patients of group A (out of 317) and 23 of group B, with metastatic
lymph nodes, underwent ALND. Tables 2 and 3 underline there was
no statistical difference between the two groups, when Non
Sentinel Lymph Nodes (NSLN) alone were considered.4. Discussion
In the last year, thanks to several studies on sentinel node, we
have better understood the anatomy of lymphatic drainage of the
breast. Up to now, scientiﬁc literature has reported different
lymphatic drainages for different areas of the breast. With the use
of lymphatic mapping and the increased experience in SLNB, thereTable 2
NSLNs involvement after ADLN in SLN positive patients.
Group A Group B p
Micrometastases
Negative N
81 (26.1%) 5 (21.7%) N.S
Micrometastases
Positive N
15 (4.8%) 1 (4.3%) N.S
Macrometastases
Negative N
94 (30.3%) 9 (39.1%) N.S
Macrometastases
Positive N
120 (38.7%) 8 (34.7%) N.Sis now increasing evidence-based support that the lymphatic ves-
sels of the mammary gland drain through a few common afferent
lymphatic trunks to speciﬁc axillary sentinel lymph nodes,
regardless of tumour location [8,9]. Thanks to this new concept,
indications for SLNB have been improved. For instance, currently,
SLNB in multicentric and multifocal clinically node-negative breast
cancer is feasible, with high sensitivity and speciﬁcity and low
false-negative rates, and no axillary recurrence [10,11].
Interestingly, different authors have reported different rates of
incidence of skip metastases. Gaglia et al. [12] reported an inci-
dence of 19.2%; in Lloyd's study [13], the 1.6% of the whole group
and the 3.2% of the positive node group showed positive LNs in
Level IIeIII with no metastasis in Level I, whereas in other studies
the incidence was 5.5% and 8.7% [14] and 7.9% and 14.6% [15],
respectively. Rosen reported an overall incidence rate for skip
metastases of 1.6% and 3% in positive node group [5], whereas
Keskek [16] reported axillary skip metastases in 4.75% of the total
and in 10% of those patients with axillary metastases.
Already in 1984, Pigott et al. [17] estimated that at least 10% of all
women with carcinoma of the breast had been understaged by an
axillary node sampling. That was because in 25% of cases the ﬁrst
level was skipped, being the metastasis present at the second or
third level LNs (skip metastases).
Finally, Parmar et al. evidenced no statistical difference between
false-negative rates of SLNB and axillary sampling [18].
In our case, we reported the presence of a SLN in 69 patients out
of 889 or 7.7%, but considering only positive node group, we found
23 cases of second level SLN, equal to 2.6%.Therefore, the involve-
ment of the lymph nodes occurs in a stepwise continuous fashion
from periphery of the axilla in 97.4% of patients.
5. Conclusion
Second level SLN could be considered only an anomalous
lymphatic axillary drainage and it does not linked to particular
histological variants of the primitive tumour. In our study, skip
metastases were recognized in only 2.6% of cases, therefore,
whenever a SLN is not isolated for any reason, the ﬁrst level sam-
pling represent a viable operative choice.
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